Efficacy and Safety of Inhaled Indacaterol and Tiotropium in Patients of Chronic Obstructive Pulmonary Disease

Mohammad Sajid Alam; Jameel Ahmad; Anil Kumar; Mohammad Shameem

doi:10.5530/ijpi.2020.2.40

Mohammad Sajid Alam Pharmacology and Department of Tuberculosis and Respiratory diseases of J.N. Medical College and Hospital, A.M.U., Aligarh, Uttar Pradesh, INDIA.
Jameel Ahmad Pharmacology and Department of Tuberculosis and Respiratory diseases of J.N. Medical College and Hospital, A.M.U., Aligarh, Uttar Pradesh, INDIA.
Anil Kumar Pharmacology and Department of Tuberculosis and Respiratory diseases of J.N. Medical College and Hospital, A.M.U., Aligarh, Uttar Pradesh, INDIA.
Mohammad Shameem Pharmacology and Department of Tuberculosis and Respiratory diseases of J.N. Medical College and Hospital, A.M.U., Aligarh, Uttar Pradesh, INDIA.

DOI: https://doi.org/10.5530/ijpi.2020.2.40

Keywords: COPD, FEV1, GOLD, SGRQ, Symptom score

Abstract

Introduction: Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide. Indacaterol is a new once daily inhaled bronchodilator, recently approved for the treatment of COPD. Once daily dosing is an important step to improve the adherence and compliance of the patients. Methods: Efficacy and Safety of Indacaterol and Tiotropium in Patients of COPD with Stage-2 and Stage-3 GOLD criteria were compared. Total 119 patients were divided into Indacaterol group and Tiotropium group receiving 150 mcg daily of Indacaterol and 18 mcg daily of Tiotropium in each group respectively. Efficacy treatment was determined by assessment of Pulmonary function test (PFT), Symptom score and SGRQ (St. George’s Respiratory Questionnaires) score at day zero (before therapeutic intervention) and at two weeks of interval till 24 weeks. Results: The treatment with inhaled indacaterol 150 mcg once daily and inhaled tiotropium 18 mcg once daily improved spirometric variable, FEV1, decrease in mean Symptoms score and in mean SGRQ in Grade-2 and Grade-3 COPD patients. Conclusion: Indacaterol (150 mcg/day) is non-inferior to tiotropium (18 mcg /day) in efficacy and safety profile of Grade-2 and Grade-3 patients with COPD.

Downloads

Download data is not yet available.